Targeting PSMA for Prostate Cancer Diagnosis and Treatment
Official title: PSMA’s enzymatic activity as new target for Prostate Cancer diagnosis and therapy
Funded at Sloan-Kettering Inst Can Research · NIH-11114031 · Data updated 2026-11-12
This project explores a new way to find and treat advanced prostate cancer by focusing on a specific protein called PSMA.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 1, 2021 |
| Project end | June 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $734,548 |
| NIH project number | 5R01CA257811-05 |
| Project ID | NIH-11114031 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with aggressive prostate cancer, particularly those whose cancer has become resistant to hormone therapy, might be ideal candidates for future applications of this research.
✕Less likely to help
Patients with early-stage prostate cancer that responds well to existing hormone therapies may not directly benefit from this specific approach.
What this research studies
Many prostate cancer patients initially respond to hormone therapy, but their cancer often becomes resistant and progresses to a more aggressive form that is very difficult to treat. Our team has uncovered a new function of a protein called PSMA, which is found at high levels in aggressive prostate cancer and helps the cancer grow. This research aims to stop prostate cancer growth by blocking this newly discovered activity of PSMA. We hope to develop a completely new, personalized treatment strategy that is different from current therapies. Additionally, we are working on a new imaging method to better diagnose and monitor prostate cancer.
Why it matters
Potential benefit: If successful, this could offer a new, personalized treatment option and improved diagnostic tools for patients with advanced prostate cancer that has become resistant to standard hormone therapy.
How similar studies have gone: This approach is based on a newly discovered biological function of PSMA, making it a novel strategy for prostate cancer treatment.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Grimm, Jan — Sloan-Kettering Inst Can Research
- Study coordinator: Grimm, Jan
Related research
Other NIH-funded projects on the same topics.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Using advanced digital imaging and AI to improve prostate cancer diagnosis
This study is working on using advanced computer technology to help doctors better understand prostate cancer by analyzing tissue samples, making it easier to spot tumors and explain the results clearly.
-
Improving prostate cancer diagnosis using advanced ultrasound techniques
This study is testing a new type of ultrasound to help doctors find serious prostate cancer more accurately and affordably, so patients can get the right treatment without unnecessary procedures for less aggressive cases.
-
Investigating a new target for diagnosing and treating prostate cancer
This study is looking at how a specific protein called PSMA affects prostate cancer, especially when it becomes harder to treat after hormone therapy, and aims to create new personalized treatments and better ways to diagnose and track the disease for patients.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.